Abstract
Transcatheter arterial embolization with hydroxycamptothecine, cantharidin and cisplatin, thoroughly mixed with large doses of interferon and interleukin-2, was performed in 48 cases with unresectable intermediate or advanced hepatocellular carcinoma. The results demonstrate a partial remission rate of 54.2%, significantly higher than that in embolization with chemotherapeutic agents alone (cisplatin, adriamycin and mitomycin, 32.1%,P<0.01). Morever, the adverse reactions of hydroxycamptothecine and cantharidin, when applied systemically, including hematuria or urodynia were successfully eliminated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
1977; 8:31.
1983; 1:22.
1992; 11:2.
1990:7–9
1974; 3:207.
1981; 1:35.
1990:244–246.
1990; 16:10.
Ikeda K, et al. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma: An analysis by the Cox proportional hazard model. Cancer 1991; 68(10):2150.
Brimm EA, et al. Lymphokine-activated killer cell phenomenon; lysis of natural killer-resistant fresh tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155:1823.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yu, Zj., Meng, Xy., Xu, Kc. et al. Hydroxycamptothecine and cantharidin combined with cisplatin and lipiodol through transcatheter arterial embolization in hepatocellular carcinoma. CJIM 1, 175–178 (1995). https://doi.org/10.1007/BF02942930
Issue Date:
DOI: https://doi.org/10.1007/BF02942930